

3 April 2017

THIS DOCUMENT HAS NOT BEEN PRODUCED BY KBC SECURITIES USA, INC.


QUEST FOR GROWTH

Benefits from Ogeda's acquisition

EQUITY INVESTMENT INSTRUMENTS
BELGIUM

CURRENT PRICE €7.33
TARGET PRICE €8.10

HOLD
RATING UNCHANGED



Source: Thomson Reuters Datastream

Bloomberg	QFG BB
Reuters	QUFG.BR
www.questforgrowth.com	
Market Cap	€84.5m
Shares outst.	11.5m
Volume (daily)	€134,015
Free float	72.9%
Next corporate event	

(€m)	2013	2014	2015
Net result	18.5	8.7	37.9
Adj. net result	18.5	8.7	37.9
Basic EPS (€)	1.60	0.76	3.29
ROE	17.3%	7.9%	34.5%
Adj. eq. value	10.87	10.28	10.81
Premium/disc.	24.5%	26.0%	-5.5%
DPS (€)	1.18	0.72	3.72
Dividend yield	14.4%	9.5%	32.6%

Cédric Duinslaeger

+32 2 429 45 04

cedric.duinslaeger@kbcsecurities.be

Positive news that Quest for Growth benefits from Ogeda's acquisition. We increase our Target Price to €8.1.

Astellas Pharma announced its intention to acquire Ogeda, a portfolio company of Quest for Growth's Capricorn Health tech fund.

Ogeda is a healthcare company focused on discovery of small molecules targeting GProtein Coupled Receptors (GPCRs). It is developing a pipeline of proprietary and partnered products. Its most advanced product is Fezolinetant. Fenzolinetant has successfully completed a phase IIa trial in hot flashes and has potential to be developed in other sex hormone disorders, including uterine fibroids & polycystic ovarian syndrome.

Astellas has agreed to pay up to a total of EUR 800 million, with an initial payment of €500m in consideration of 100% of equity. An additional €300m will be eligible for Ogeda's shareholders with attainment of certain clinical development and regulatory milestones for fezolinetant. Ogeda would become a fully owned subsidiary of Astellas. The closing of the transaction is submitted to certain conditions and is expected to be finalized in the second quarter of 2017.

Conclusion:

The announced transaction is the first significant successful divestment of Capricorn Health-tech Fund. Earlier, in 2015, Capricorn ICT Arkiv realised the successful exit of its investment in Cartagena.

Capricorn ICT Arkiv realized the successful exit of its investment in Cartagena. Quest for Growth says that a positive impact on Quest for Growth's NAV of about €8.6m, or €0.57 per share.

We increase our Target Price to €8.1 and maintain our Hold rating.